Coverage & method

Intelligence you can defend.

Decision-grade intelligence requires decision-grade provenance. Here is how the LAI dataset is scoped, classified, and sourced.

The boundary

What counts as a long-acting injectable.

The scope is a deliberate, documented decision, not the result of a keyword search, and it is revisited as the field evolves. An asset is in scope when its long duration is engineered: obtained from an identifiable delivery or half-life-extension technology, by an injectable route, and lasting far longer than the drug would on its own. Deliberately out of scope: vaccines, cell and gene therapies, surgically-placed or non-resorbable implants, and antibodies whose long half-life is natural rather than engineered.

The technology map

The technology, classified.

Long-acting injection is, first, an engineering question: how a molecule is made to last. That is why the technology taxonomy is the core of Vectora. We separate what extends the action from what carries it, on independent axes that combine: an asset can be a physical depot, of a given matrix, on a given route.

Drug delivery systems (DDS)

Physical release

MicrosphereNanocrystalNanoparticleIn-situ depotGel depotImplantLiposomeOil depot

Chemical release

Prodrug (ester, amide)Cleavable conjugate

Matrix material

PolymerLipidHydrogelInorganic

Half-life extension (HLE)

Mechanism

PEGylationLipidationAlbumin-bindingFc-fusionGlyco-engineeringProtein-fusion extender

Every asset is placed on these axes. Where a mechanism is a named, proprietary platform, it is tracked as such, not flattened into a generic label.

Inputs & cadence

Public inputs, monitored year-round.

The raw material is public: regulatory bodies such as the FDA and EMA, clinical registries, the scientific literature, corporate disclosures. It is monitored continuously, so the picture tracks the field as it moves, not a yearly snapshot. What turns those scattered signals into intelligence is proprietary: the ontology, the delivery-technology taxonomy, and the curation decisions that resolve every entity into a single, queryable whole.

Provenance

Where each value comes from.

Regulatory facts, linked to source

Where an FDA or EMA label exists, its facts carry a link to the official source: DailyMed for the FDA, the EMA register. Open the document and read it yourself; the source is one click away.

Everything else, curated to the ontology

Delivery technology, release families, molecular properties, targets and more are captured, curated and resolved into Vectora’s ontology, consistent and comparable across the whole scope.

Curation

Governed by domain expertise.

The ontology, the delivery-technology taxonomy, and the scope are defined and maintained by an analyst with eleven years in pharmaceutical competitive intelligence. Those editorial decisions, what qualifies and how a technology is classified, are the work no generalist database has done for this niche.